se of Sugammadex or Neostigmine as reversal agent for Neuromuscular Blockade in obese patients.
Phase 3
- Conditions
- Health Condition 1: E660- Obesity due to excess calories
- Registration Number
- CTRI/2024/02/063037
- Lead Sponsor
- Dr Sumedha Mehta
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1) Obese patients
2) Obese patients undergoing general anesthesia requiring muscle relaxants.
Exclusion Criteria
1)Difficult Airway
2) Neuromuscular disorder that could impair neuromuscular blockade.
3) Significant renal or hepatic dysfunction.
4) Family history of malignant hyperthermia.
5) Patients receiving medication (for example: magnesium, anticonvulsants, aminoglycosides) expected to interfere with the muscle relaxant.
6) Patients requiring post -operative ventilator support.
7) Patients already intubated or tracheostomized.
8) Patient refusal.
9) Pregnant or lactating women.
10) Any allergy to study drugs
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare efficacy of Sugammadex and Neostigmine in reversing neuromuscular blockade in terms of duration of the complete recovery from neuromuscular blocking agents (TOF 0.9)and time to extubation.Timepoint: At end of surgey, patients will receive either a dose of sugammadex (2 mg/kg), as an i.v. bolus (within 10 s) into a fast-running saline infusion or Inj Neostigmine 0.5mg/kg with glycopyrrolate(8mcg/kg) and time from drug administration and complete NMB reversal (TOF ratio = 0.9) <br/ ><br> and time to extubation will be noted.
- Secondary Outcome Measures
Name Time Method The secondary outcome will be incidence of postoperative curarization or pulmonary complications such as cough, breath holding, increased secretion, desaturation (SpO2=90), decreased breath frequency, pneumonia, reintubation, ICU admission, bradycardia, & hypotension seen within 24 hours of Inj Sugammadex or Inj Neostigmine administration.Timepoint: Any complications or side effects from the time of Inj Sugammadex or Inj Neostigmine Administration till 24hrs postoperatively.